UNSPSC 51161722: Almitrine bismesylate

This classification denotes a cns stimulant with the molecular formula C26H29F2N7.2CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6RY6V6XM8T, chemically known as 6-4-(bis(4-fluorophenyl)methyl)-1-piperazinyl)-n,n'-di-2-propenyl-1,3,5-triazine-2,4-diamine dimethanesulfonate, but more generally known as almitrine bismesylate, which bears US NIH Compound Identifier 115048.

European Medicines Agency schedules almitrine bismesylate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05348MIG. Most nations, for tariff purposes, schedule almitrine bismesylate under HS 29336980. SMILES: CS(=O)(=O)O.CS(=O)(=O)O.C=CCNC1NC(NC(N1)N2CCN(CC2)C(C3CCC(CC3)F)C4CCC(CC4)F)NCC=C.

UNSPSC 51161722 Almitrine bismesylate is a Commodity code that sits at the intersection of pharmaceutical procurement and state and local health-services contracting, though recent solicitations tagged under this code do not focus on almitrine bismesylate itself but rather on broader pharmaceutical supply, pharmacy services delivery, and drug-management programs. State and local issuing bodies soliciting under or near this code include county health departments, state health commissions, and cooperative purchasing alliances administering multi-jurisdiction pharmaceutical contracts. The scope of work spans purchase and distribution of generic pharmaceuticals and over-the-counter products through authorized wholesale channels; on-site pharmacy services at government health clinics serving employees, retirees, and their families; procurement of naloxone and drug deactivation systems for community health and opioid-response initiatives; and exploratory contracting for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. Vendors must demonstrate compliance with current Good Manufacturing Practices, the Drug Supply Chain Security Act, FDA requirements, and HIPAA standards; maintain relationships with authorized wholesalers and chargeback systems; carry substantial insurance coverage (general liability, workers' compensation, cyber liability, and professional liability); and meet E-Verify and drug-free workplace requirements. Contracts typically run one to two years with optional renewal periods and are awarded on fixed-fee or competitive-pricing bases with performance penalties for late reporting or missed milestones.

Recent activity appears concentrated in the Southeast and upper Midwest. Seminole County, Florida issued IFB60459723LAS (due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, supporting community health initiatives and potentially funded through FEMA. Hall County, Georgia issued RFQ/P #47-010 (due June 4, 2026) for on-site pharmacy services at its Family Health Center Clinic in Gainesville, serving approximately 3,005 eligible individuals across multiple health plan populations, with evaluation weighted 80 percent technical qualifications and 20 percent cost. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities including Oregon, with awarded vendors required to work through AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC, and pricing weighted at 75 percent of evaluation. The Texas Health and Human Services Commission issued RFI No. HHS0017013 (posted March 27, 2026, response due April 3, 2026) to gather market intelligence on direct-to-manufacturer prescription contracting outside traditional PBM and GPO arrangements, signaling exploratory interest in alternative supply models for self-insured plans.